THERAPEUTIC DRUG MONITORING DOSING REGIMEN WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY

J.-F Colombel  ¹     Julian Panés  ²     G.R D'Haens  ³     S. Schreiber  ⁴     R. Panaccione  ⁵     L. Peyrin-Biroulet  ⁶     E.V Loftus Jr  ⁷     Silvio Danese  ⁸     E. Louis  ⁹     Alessandro Armuzzi  ¹⁰     M. Ferrante  ¹¹     H. Vogelsang  ¹²     N.M Mostafa  ¹³     T. Doan  ¹³     W. Xie  ¹³     J. Petersson  ¹³     J. Kalabic  ¹⁴     A.M Robinson  ¹⁴     William Sandborn  ^15    
1 Icahn School of Medicine at Mt Sinai, New York, NY, United States
² Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
³ Amsterdam University Medical Centers, Amsterdam, Netherlands
⁴ University Hospital Schleswig-Holstein, Kiel, Germany
⁵ University of Calgary, Calgary, AB, Canada
⁶ University Hospital of Nancy, Lorraine University, Vandoeuvre, France
⁷ Mayo Clinic, Rochester, MN, United States
⁸ Istituto Clinico Humanitas, Rozzano, Milan, Italy
⁹ University Hospital CHU of Liège, Liège, Belgium, Belgium
¹⁰ Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
¹¹ University Hospitals Leuven, Leuven, Belgium
¹² Medical University of Vienna, Vienna, Austria
¹³ AbbVie Inc., North Chicago, IL, United States
¹⁴ AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
¹⁵ University of California San Diego, La Jolla, CA, United States

Session
IBD Clinical I

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)